ESTRO Annual Report 2019

Radiother Oncol 2019, in press (RO-D-19-00638). DOI: 10.1016/j.radonc.2019.09.020

Besides two other publications have been submitted: one on a practical model application in Belgium focusing on estimating the cost of oligometastatic diseases treated with stereotactic techniques and exploring the impact on the national budget of introducing this new reimbursement tariff; another one on the cost-accountingmethodological specificities of developing a TD-ABC at national level, illustrated by national experiences in applying the ESTRO- HERO Tool and their public policy implications.

38